Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

The FDA has approved Soliris the first-ever treatment for children with generalized myasthenia gravis gMG offering new hope in pediatric neuromuscular care Learn more!

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...

The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.